About Event

Retuning for its 2nd digital event, the industry-dedicated Gene Therapy for Ophthalmic Disorders will allow you to:

Transparent

Hear the latest data in ocular gene therapy immunogenicity and vector strategies to overcome Inflammation

Transparent

Highlight optogenetics and gene agnostic approaches from SparingVision, GenSight Biologics and Bionic Sight

Transparent

Learn how Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures

Transparent

Discuss the clinical progress with different administration routes to the eye with clinical experience from REGENXBIO

Transparent

Gain key vector insights from Eyevensys, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing

Transparent

Explore the realities of clinical trial design to meet regulatory expectations throughout a program, with insights from Gensight Biologics

Transparent

Hear pharma representatives discuss the opportunities and realities of collaborating with biotechs, with experience from Novartis

Transparent

Hear from a Luxturna patient to understand their first-hand experience of receiving the therapy, and have an opportunity to ask them your questions

Transparent

Highlighting progress in ASOs for ophthalmic disorders for a deeper understanding of the ophthalmic landscape with data from ProQR